MASS-FIX (MALDI-TOF MS)
A groundbreaking approach to monoclonal protein identification
For patients at risk of plasma cell disorders, early identification is critical to ensure better outcomes. Coined as MASS-FIX, our innovative approach uses matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), and marks the first major breakthrough in multiple myeloma screening since gel electrophoresis was developed in 1967.
By weighing M-proteins, we overcome electrophoresis’s limitations in detection and provide the most accurate understanding of a patient’s M-proteins. This novel MASS-FIX testing also helps health care providers understand their patients’ risk of progression to multiple myeloma, (AL) amyloidosis or other diseases. This level of insight is not possible with traditional testing methods.
The impact of MASS-FIX extends beyond the hematologic systems into renal and neurologic spheres. As more is learned about the molecular, cytogenic, and protein variations of M-protein disorders, clinicians have discovered additional disease associations. Learn more here.
Multiple Myeloma and MASS-FIX Testing Updates
Watch this video to learn more about updates on multiple myeloma and MASS-FIX: Hot topics, challenges, and solutions for the clinical lab and patient care.
Now included in International Myeloma Working Group recommendations
Superior testing for optimal patient care
The new MASS-FIX testing method provides:
Screening and diagnosis
DMOGA | Monoclonal Gammopathy, Diagnostic, Serum
Analytic time: 2 days
PEISO | Protein Electrophoresis and Isotype, Serum
Analytic time: 2 days
SPEP | Electrophoresis, Protein, Serum
Analytic time: 2 - 5 days
After diagnosis or amyloidosis suspicion
SMPU | Monoclonal Protein Screen, 24 Hour, Urine
Analytic time: 4–6 days
RSMPU | Monoclonal Protein Screen, Random, Urine
Analytic time: 4–6 days
Monitoring
TMOGA | Monoclonal Gammopathy, Monitoring, Serum
Analytic time: Same day/1 day
Analytic time: Same day/1 day
How an ex-NFL linebacker overcame his greatest opponent, amyloidosis
Matt Millen, an ex-pro NFL player who played on four Super Bowl-winning teams, underwent a nearly six-year medical journey in search for answers. Finally, he was diagnosed with amyloidosis using a new testing methodology at Mayo Clinic.